These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 26949913)

  • 1. A phase 1/2a study to test the safety and immunogenicity of a p16(INK4a) peptide vaccine in patients with advanced human papillomavirus-associated cancers.
    Reuschenbach M; Pauligk C; Karbach J; Rafiyan MR; Kloor M; Prigge ES; Sauer M; Al-Batran SE; Kaufmann AM; Schneider A; Jäger E; von Knebel Doeberitz M
    Cancer; 2016 May; 122(9):1425-33. PubMed ID: 26949913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Targeting p16(INK4a) by therapeutic vaccination : Concept and status of clinical investigations in HPV-associated head and neck cancers].
    Reuschenbach M
    HNO; 2015 Feb; 63(2):104-10. PubMed ID: 25515124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No evidence of oncogenic KRAS mutations in squamous cell carcinomas of the anogenital tract and head and neck region independent of human papillomavirus and p16(INK4a) status.
    Prigge ES; Urban K; Stiegler S; Müller M; Kloor M; Mai S; Ottstadt M; Lohr F; Wenz F; Wagner S; Wittekindt C; Klussmann JP; Hampl M; von Knebel Doeberitz M; Reuschenbach M
    Hum Pathol; 2014 Nov; 45(11):2347-54. PubMed ID: 25257576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-associated cancers.
    Reuschenbach M; Waterboer T; Wallin KL; Einenkel J; Dillner J; Hamsikova E; Eschenbach D; Zimmer H; Heilig B; Kopitz J; Pawlita M; Doeberitz Mv; Wentzensen N
    Int J Cancer; 2008 Dec; 123(11):2626-31. PubMed ID: 18785210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulation of expression and lack of 5' CpG island hypermethylation of p16 INK4a in HPV-positive cervical carcinomas.
    Ivanova TA; Golovina DA; Zavalishina LE; Volgareva GM; Katargin AN; Andreeva YY; Frank GA; Kisseljov FL; Kisseljova NP
    BMC Cancer; 2007 Mar; 7():47. PubMed ID: 17359536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p16(INK4a) overexpression predicts translational active human papillomavirus infection in tonsillar cancer.
    Hoffmann M; Ihloff AS; Görögh T; Weise JB; Fazel A; Krams M; Rittgen W; Schwarz E; Kahn T
    Int J Cancer; 2010 Oct; 127(7):1595-602. PubMed ID: 20091864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of p16(INK4a) /Ki67 immunocytology and HPV polymerase chain reaction for the noninvasive analysis of HPV involvement in head and neck cancer.
    Linxweiler M; Bochen F; Wemmert S; Lerner C; Hasenfus A; Bohle RM; Al-Kadah B; Takacs ZF; Smola S; Schick B
    Cancer Cytopathol; 2015 Apr; 123(4):219-29. PubMed ID: 25557267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
    Kakimi K; Isobe M; Uenaka A; Wada H; Sato E; Doki Y; Nakajima J; Seto Y; Yamatsuji T; Naomoto Y; Shiraishi K; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Oka M; Pan L; Hoffman EW; Old LJ; Nakayama E
    Int J Cancer; 2011 Dec; 129(12):2836-46. PubMed ID: 21448901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between p14(ARF)/p16(INK4A) expression and HPV infection in uterine cervical cancer.
    Kanao H; Enomoto T; Ueda Y; Fujita M; Nakashima R; Ueno Y; Miyatake T; Yoshizaki T; Buzard GS; Kimura T; Yoshino K; Murata Y
    Cancer Lett; 2004 Sep; 213(1):31-7. PubMed ID: 15312681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck.
    Lassen P; Eriksen JG; Hamilton-Dutoit S; Tramm T; Alsner J; Overgaard J
    J Clin Oncol; 2009 Apr; 27(12):1992-8. PubMed ID: 19289615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1.
    Garcia-Bates TM; Kim E; Concha-Benavente F; Trivedi S; Mailliard RB; Gambotto A; Ferris RL
    J Immunol; 2016 Mar; 196(6):2870-8. PubMed ID: 26851223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human papillomavirus infection in Bowen disease: negative p53 expression, not p16(INK4a) overexpression, is correlated with human papillomavirus-associated Bowen disease.
    Murao K; Yoshioka R; Kubo Y
    J Dermatol; 2014 Oct; 41(10):878-84. PubMed ID: 25201325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
    Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
    Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interpretation of p16(INK4a) /Ki-67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology.
    Allia E; Ronco G; Coccia A; Luparia P; Macrì L; Fiorito C; Maletta F; Deambrogio C; Tunesi S; De Marco L; Gillio-Tos A; Sapino A; Ghiringhello B
    Cancer Cytopathol; 2015 Apr; 123(4):212-8. PubMed ID: 25534957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of Human Papillomavirus as a Favourable Prognostic Marker and Analysis of CD8
    Sivars L; Landin D; Grün N; Vlastos A; Marklund L; Nordemar S; Ramqvist T; Munck-Wikland E; Näsman A; Dalianis T
    Anticancer Res; 2017 Feb; 37(2):665-673. PubMed ID: 28179315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P16INK4a expression, human papillomavirus, and survival in head and neck cancer.
    Smith EM; Wang D; Kim Y; Rubenstein LM; Lee JH; Haugen TH; Turek LP
    Oral Oncol; 2008 Feb; 44(2):133-42. PubMed ID: 17360226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7.
    Steller MA; Gurski KJ; Murakami M; Daniel RW; Shah KV; Celis E; Sette A; Trimble EL; Park RC; Marincola FM
    Clin Cancer Res; 1998 Sep; 4(9):2103-9. PubMed ID: 9748126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for at least three alternative mechanisms targeting the p16INK4A/cyclin D/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus.
    Ferreux E; Lont AP; Horenblas S; Gallee MP; Raaphorst FM; von Knebel Doeberitz M; Meijer CJ; Snijders PJ
    J Pathol; 2003 Sep; 201(1):109-18. PubMed ID: 12950023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
    Wada H; Isobe M; Kakimi K; Mizote Y; Eikawa S; Sato E; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Yamasaki M; Miyata H; Matsushita H; Udono H; Seto Y; Yamada K; Nishikawa H; Pan L; Venhaus R; Oka M; Doki Y; Nakayama E
    J Immunother; 2014; 37(2):84-92. PubMed ID: 24509171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.